Exelixis Inc

Links: Y! EXEL chart/quote @ Y! F

EXEL / Message Board

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
22959	Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR)	GN	Pacific		3	10/22/2019 10:26:29 PM

22958	Re: WTF????	GN	TaiTienMuyBien		0	10/22/2019 10:06:17 PM

22957	Re: WTF????	GN	toohearn		1	10/22/2019 6:17:05 PM

22956	Typical October Hangover!	GN	simbha		0	10/22/2019 5:33:50 PM

22955	Re: WTF???? On second thought..	GN	enabeler		1	10/22/2019 12:17:23 PM

22954	Re: WTF????	GN	Pharma311		1	10/22/2019 11:37:46 AM

22953	WTF????	GN	enabeler	Strong Buy	5	10/22/2019 10:23:19 AM

22952	Kidney Cancer: What Is New in the Second-Line Treatment Setting?	GN	Pacific		4	10/21/2019 3:22:44 PM

22951	Roche's Tecentriq scores a first-in-class double win in new liver cancer patients	GN	Pacific		3	10/21/2019 1:06:18 PM

22950	Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)	GN	rad.onco		2	10/20/2019 12:28:20 PM


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement